Regenxbio Says Initial Interim Data From A First-In-Human Trial Of RGX-181 For Late-infantile Neuronal Ceroid Lipofuscinosis Type 2 Disease, A Form Of Batten Disease, Were Presented At The Society For The Study Of Inborn Errors Of Metabolism
Portfolio Pulse from Benzinga Newsdesk
Regenxbio has presented initial interim data from a first-in-human trial of RGX-181 for late-infantile neuronal ceroid lipofuscinosis type 2 disease, a form of Batten disease, at the Society for the Study of Inborn Errors of Metabolism.
August 30, 2023 | 11:14 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Regenxbio's presentation of initial interim data from a trial of RGX-181 could potentially impact the company's stock in the short term.
The presentation of initial interim data from a trial is a significant event for a biotech company like Regenxbio. While the news does not provide specific results, it indicates progress in the company's research and development efforts. This could potentially influence investor sentiment and impact the company's stock. However, without specific results, it's difficult to predict the direction of the impact.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100